CKD

Minuteful Kidney From Healthy.io Named "Best Overall Mobile Health Solution" in 2024 MedTech Breakthrough Awards Program

Retrieved on: 
星期四, 五月 9, 2024
Medtech, FDA, Kidney disease, Kidney, Healthy.io, AI, Health, EHR, Electronic health record, Smartphone, CKD, Chronic kidney disease, Telehealth, Medical device, Patient, Dialysis, Microalbuminuria, Algorithm

BOSTON, May 9, 2024 /PRNewswire/ -- Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced that Minuteful Kidney has been selected as "Best Overall Mobile Health Solution" in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.

Key Points: 
  • It measures urine albumin-creatinine ratio (uACR) to detect kidney damage, supporting the identification of chronic kidney disease (CKD).
  • Guided by a user-friendly smartphone app, Minuteful Kidney allows for easy and effective home testing, instantly delivering clinical-grade results.
  • "We are delighted that MedTech Breakthrough has recognized Minuteful Kidney as the Best Overall Mobile Health Solution in this year's awards.
  • These life-altering consequences makes it our choice for 'Best Overall Mobile Health Solution!'"

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 9, 2024
Investment, Glomerular filtration rate, Safety, Conference call, Research, Heart, Aldosterone, Research and development, Insurance, Conference, Administration, EGFR, Obesity, CKD, Patient, Pivotal, SGLT2, Hypertension, Therapy, Chronic kidney disease, G&A, Pharmaceutical industry

RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) --  Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.

Key Points: 
  • ET –
    RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) --  Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.
  • General and Administrative (G&A) expenses were $4.6 million for the quarter ended March 31, 2024, compared to $2.6 million for the quarter ended March 31, 2023.
  • Total other income, net was $3.9 million for the quarter ended March 31, 2024, compared to $2.3 million for the quarter ended March 31, 2023.
  • Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.

FibroGen Reports First Quarter 2024 Financial Results

Retrieved on: 
星期一, 五月 6, 2024
Pamrevlumab, Sale, Investment, Peripheral neuropathy, Pancreatic cancer, Neutropenia, RECIST, LAPC, CD46, Weight loss, MD, PSA, Webcast, Growth, IND, ASCO, CKD, Patient, Fatigue, Neoplasm, SAN, AstraZeneca, Anemia, CIA, Interest, Pharmaceutical industry

Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.

Key Points: 
  • Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
  • Total revenue for the first quarter of 2024 was $55.9 million, as compared to $36.2 million for the first quarter of 2023, an increase of 55% year over year.
  • At March 31, 2024, FibroGen reported $214.7 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.
  • FibroGen will host a conference call and webcast today, Monday, May 6, 2024, at 5:00 PM Eastern Time to discuss financial results and provide a business update.

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Retrieved on: 
星期一, 五月 6, 2024
CKD, Therapy, Chronic kidney disease, Bank, Conference, Hypertension

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.

Key Points: 
  • RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
  • Bank of America Securities Health Care Conference:

Carna Health Names Leadership Team and Presents Strong Results from Bermuda CKD Screening Program

Retrieved on: 
星期四, 五月 9, 2024
Software, Telemedicine, Virtual Medicine, General Health, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Mortality, Public, Kidney disease, Nephrology, Hospital, Prevalence, Death, Partnership, MSBA, Oscar Health, Joslin Diabetes Center, Intelligence, CKD, Patient, Bill, MPH, Dialysis, Faculty, Ministry, Harvard Medical School, MBA, BBA, Quality of life, Chronic kidney disease, MHA, IBM, Management

Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.

Key Points: 
  • Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.
  • “Our shared commitment with Carna Health to develop new screening and monitoring programs for CKD at sites outside the hospital is essential to our partnership.
  • “The results from the screening program in Bermuda demonstrate the feasibility of cost-effective, large-scale population screening and monitoring for CKD – and the high rate of undiagnosed CKD that needs to be addressed so we can prioritize prevention and earlier disease management,” said Carna Health CMO and COO Shika Pappoe, MD, MPH, MBA.
  • In just three days the program surpassed its screening target, drawing more than 550 participants.

Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease

Retrieved on: 
星期三, 五月 8, 2024
Technology, Hospitals, Diabetes, Health Technology, Practice Management, Health, Pharmaceutical, General Health, Artificial Intelligence, Conditional sentence, Acos, Organization, Hospital, National Kidney Foundation, Health equity, Group purchasing organization, Diagnosis, Uncover, Partnership, Conference, Artificial intelligence, Workflow, Pharmacy, Kidney disease, CKD, Science, Patient, RWD, Physician, Premier, Medical missions, Exhibition, PAS, Algorithm, AstraZeneca, Prevalence

Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.

Key Points: 
  • Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.
  • The partnership with AstraZeneca demonstrates a commitment to implement and learn about innovative approaches to driving optimization of guideline-directed medical therapy for patients.
  • PINC AI™ Stanson AI-powered technology, including clinical decision support and real-time alerts integrated into the provider workflow, to help strategically modify provider behavior to improve CKD screening, diagnosis and care quality.
  • For example, these resources could include the CKD Care Journey Roadmap, CKD Health Equity Primer, clinical decision support documentation (algorithms) and other digitized resources.

CYNTHIA DELGADO AND NEIL POWE NAMED TO TIME100 HEALTH LIST FOR FIGHTING KIDNEY TRANSPLANT BIAS

Retrieved on: 
星期四, 五月 2, 2024
Task force, FASN, National Kidney Foundation, Filtration, Risk, Kidney failure, Health, Kidney, Cystatin C, GFR, Black, TIME, Creatinine, CKD, Organ, Patient, American Society of Nephrology, Society, MPH, Kidney transplantation, ASN, MBA, NKF, Chronic kidney disease, Pioneer, Global health, Nursing

The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.

Key Points: 
  • The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.
  • TIME included NKF/ASN Task Force co-chairs in its first-ever list of the 100 most influential people in global health.
  • Under the updated, race-free algorithm, some Black patients recently received modified times on the wait list for a kidney transplant.
  • The TIME100 Health List recognizes the world's most influential individuals in health across five categories: Innovators, Titans, Pioneers, Leaders, and Catalysts.

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 2, 2024
Shift, FDA, Albuminuria, Investment, Research, Webcast, Chronic kidney disease, Endothelium, PROGRESS, American College of Cardiology, ASN, ID, AAK1, Overalls, Heart failure, Treatment, Conference, HCM, Neuropathic pain, Quality of life, Diabetes, Patient, SGLT2 inhibitor, Travel, Diabetic ketoacidosis, Obesity, CKD, Marketing, Research and development, American College, Vessel, Insulin, Diabetes management, Inhibitor, NDA, Coagulation, Administration, Society, Lexicon, Risk, Growth, Lexicon Pharmaceuticals, Pharmaceutical industry

Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.

Key Points: 
  • Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
  • Lexicon is initiating a Phase 3 study of sotagliflozin in HCM, with an expected study start mid-year 2024.
  • Results from Two Large US Integrated Health System
    Revenues: Revenues for the first quarter of 2024 were $1.1 million, primarily from the commercialization of INPEFA.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
星期四, 四月 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Retrieved on: 
星期二, 四月 23, 2024
CMS, Tablet, Desidustat, NMPA, NDA, National Medical Products Administration, Kidney failure, New Drug Application, Erythropoiesis, Anemia, Chronic kidney disease, CKD, Week, Patient, Dialysis, Prevalence, Marketing, Diagnosis, Advertising, EPO, Medical device

Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.

Key Points: 
  • Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.
  • The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
  • China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets  (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).
  • Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.